- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
FDA Clears deep TMS device for Smoking Addiction in Adults
![FDA Clears deep TMS device for Smoking Addiction in Adults FDA Clears deep TMS device for Smoking Addiction in Adults](https://medicaldialogues.in/h-upload/2020/04/16/750x450_127335-smoking.webp)
CRESSKILL - The US Food and Drug Administration (FDA) has granted marketing approval for the BrainsWay deep transcranial magnetic stimulation (deep TMS) system for its use as an aid in short-term smoking cessation in adults.
Smoking is one of the leading causes of death in developed countries. The addiction to nicotine, similar to the addiction to drugs and alcohol, involves modulation of the brain reward system and causes an uncontrollable desire to smoke.
"This FDA clearance represents a significant milestone for BrainsWay and our Deep TMS platform technology," stated Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. "Smoking is one of the leading causes of death in the U.S. and also leads to other serious conditions, such as lung cancer and heart disease. While other therapies are currently available, a substantial medical need continues to exist for treatments that can increase the continuous quit rate among smokers. Based on the compelling data from our large, randomized pivotal study of 262 subjects, we are confident that our Deep TMS technology can play an important role in treating cigarette smokers who seek to quit. We look forward to executing a controlled U.S. market release of our newly cleared and proprietary H4 Deep TMS coil for this indication early next year."
Dr. von Jako added, "Importantly, this is the first FDA clearance in the addiction space for any TMS device, and it represents BrainsWay's third FDA-cleared coil and indication, following the clearance of our H1-coil for patients suffering from major depressive disorder and the H7-coil as an adjunct therapy for the treatment of OCD. This latest clearance cements BrainsWay's status as an industry leader, and further demonstrates our commitment to leveraging our platform technology to advance innovative therapeutic solutions across multiple patient populations."
About the Pivotal Study
The efficacy of the BrainsWay Deep TMS System with H4-coil as an aid to short-term smoking cessation was demonstrated in a prospective, double-blind, randomized, sham-controlled, a multi-center trial which enrolled 262 eligible subjects randomized into two groups: an active treatment group treated with BrainsWay's H4 Deep TMS coil which was designed to target addiction-related brain circuits, and a sham (placebo) control group. Subjects were randomly assigned to either the active Deep TMS group or the sham group. The treatments were performed daily, five days a week for 3 weeks, followed by an additional 3 sessions once a week for 3 weeks (for a total of 18 sessions over the course of 6 weeks).
The primary endpoint of the study was a comparison between the two groups of the four-week continuous quit rate (CQR), representing abstinence during a consecutive four-week period, at any point between the start of treatment and the follow up visit four months thereafter. Weekly abstinence was defined as a subject's self-report (in a diary) of no smoking, confirmed by urine tests indicating abstinence from smoking. The participants in the study were highly addicted to smoking, with a history of smoking an average of over 26 years and multiple failed attempts to quit.
When analyzing the primary endpoint in the 262 participants comprising the full intention to treat (ITT) population (which also included subjects who did not complete the entire treatment period), the CQR was 17.1% in the active Deep TMS group and 7.9% in the sham group (p=0.0238). When analyzing subjects with 4 weeks of treatment, diary records, and confirmatory urine samples (i.e., completers), the CQR was 28.4% in the active Deep TMS group compared to 11.7% in the sham group (p=0.0063). Based on the primary efficacy analysis of the study, BrainsWay's H4 Deep TMS coil led to a positive treatment outcome and demonstrated a beneficial effect in short-term smoking cessation.
An important secondary endpoint was the number of cigarettes smoked per day (CPD), per diary entry. The difference in the average number of CPD per subject from baseline to the end of the study (4-month follow-up for quitters and 6 weeks follow-up for smokers) was statistically significantly lower in the active Deep TMS group compared to the sham group (p=0.0311).
No seizures were reported in the study, and the most common adverse event reported was headaches, which was not statistically different between the active and sham groups. Other side effects that were reported included application site discomfort, back pain, muscle twitching, and discomfort.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751